Download PDF
Thromb Haemost 2004; 91(04): 834-836
DOI: 10.1055/s-0037-1614278
Letters to the Editor
Schattauer GmbH

Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making

Leonardo Potenza
,
Mario Luppi
,
Monica Morselli
,
Alessia Saviola
,
Angela Ferrari
,
Giovanni Riva
,
Giuseppe Longo
,
Marco Marietta
,
Giuseppe Torelli
Further Information

Publication History

Received 02 September 2003

Accepted after revision 23 December 2003

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Barlogie B, Jagannath S, Desikan KR. et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
    PubMedGoogle Scholar
  • 2 Zangari M, Anaisse E, Barlogie B. et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-5.
    CrossrefPubMedGoogle Scholar
  • 3 Osman K, Comenzo R, Rajkumar V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: 1951-2.
    CrossrefPubMedGoogle Scholar
  • 4 Camba L, Peccatori J, Pescarollo A. et al. Thalidomide and thrombosis in patients with multiple myeloma. Haematologica 2001; 86: 1108-9.
    PubMedGoogle Scholar
  • 5 Cavo M, Zamagni E, Cellini C. et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line fhalidomide-dexa-methasone therapy. Blood 2002; 100: 2272.
    CrossrefPubMedGoogle Scholar
  • 6 Urbauer E, Kaufmann H, Nosslinger T. et al. Thromboembolic events during treatment with thalidomide. Blood 2002; 99: 4247-28.
    CrossrefPubMedGoogle Scholar
  • 7 Rajkumar SV, Hayman S, Gertz MA. et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncology 2002; 20: 4319-23.
    CrossrefPubMedGoogle Scholar
  • 8 Anagnostopoulos A, Weber D, Rankin K. et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768-71.
    CrossrefPubMedGoogle Scholar
  • 9 Lee CK, Barlogie B, Munshi N. et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncology 2003; 21: 2732-9.
    CrossrefPubMedGoogle Scholar
  • 10 Zangari M, Saghafifar F, Anaisse E. et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complication. Blood Coagul Fibrinolysis 2002; 13: 187-92.
    CrossrefPubMedGoogle Scholar
  • 11 Minnema MC, Fijnheer R, De Groot PG. et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 01: 445-9.
    CrossrefPubMedGoogle Scholar
  • 12 Santos AB, Llamas P, Roman A. et al. Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt. Br J Haematol 2003; 122: 159-67.
    CrossrefPubMedGoogle Scholar
  • 13 Barlogie B, Desikan R, Eddlemon P. et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-4.
    CrossrefPubMedGoogle Scholar
  • 14 Rajkumar SV, Gertz MA, Lacy MQ. et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-9.
    CrossrefPubMedGoogle Scholar
  • 15 Flageul B, Wallach D, Cavelier-Balloy B. et al. Thalidomide and thrombosis. Ann Dermatol Venereol 2000; 127: 171-4.
    PubMedGoogle Scholar
  • 16 Otterson GA, Monahan BP, Harold N. et al. Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am J Med 1996; 101: 406-12.
    CrossrefPubMedGoogle Scholar
  • 17 Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-28.
    CrossrefPubMedGoogle Scholar
  • 18 Kraaijenhagen RA, in’t Anker PS, Koopman MM. et al. High plasma concentration of factor VIIIc is a major risk for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Tso E, Baz R, Marchant K. et al. Aspirin (ASA) prophylaxis during treatment of multiple myeloma using liposomal doxorubicin, vincristine, decreased-frequency dexametha-sone and thalidomide decreases post-treatment thrombosis. ASCO 2003; 2349a.
    PubMedGoogle Scholar